Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC

Sign up for our daily newsletter

Abuse-deterrent painkiller fails study goal, drugmaker Acura’s shares fall

4:42 pm by | 0 Comments

(Reuters) - Acura Pharmaceuticals Inc said a painkiller made with its abuse-deterrent technology did not show statistically significant results in reducing likability among abusers, sending its shares down 34 percent in after-hours trading.

The study showed that Acura's tablet, Aversion H&A, had a slighter lower measure of liking when compared with the generic hydrocodone/acetaminophen tablet.

The tablet was tested for potential abuse by snorting.

The company said it expects the submission of a marketing approval application to be delayed.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.